During the COVID-19 pandemic, when and why would you consider delaying autologous transplant for patients with diffuse large B-cell lymphoma in second complete remission?
Recorded April 21, 2020.
How has the COVID-19 pandemic changed your approach to the selection of tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia?
Recorded April 24, 2020.
William A. Wood, MD, MPH, of the University of North Carolina at Chapel Hill, and Oversight Group Chair for the new COVID-19 registry, talks about why it was formed, how it can help patients and providers, and how it operates and could evolve in the future. Filmed April 3, 2020.
Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses challenges patients with multiple myeloma have faced as a result of the COVID-19 pandemic and the research he and his international colleagues are conducting to better understand these difficulties and improve patient care.
Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori in Naples, Italy, talks about minimizing risks for patients with cancer, prioritizing surgery and other treatments for melanoma, and the state of clinical trials. Filmed April 17, 2020.
